These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32338842)

  • 1. The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.
    Grandi G; Perrone AM; Toss A; Vitagliano A; Friso S; Facchinetti F; Cortesi L; Cascinu S; De Iaco P
    Minerva Med; 2020 Apr; 111(2):133-140. PubMed ID: 32338842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
    Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
    Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
    Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
    Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
    Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
    Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
    Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
    Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
    J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Value of Preoperative CA 125 Levels in Prediction of Myometrial Invasion in Patients with Early-stage Endometrioid- type Endometrial Cancer.
    Atguden Z; Yildiz A; Aksut H; Yalcin SE; Yalcin Y; Uysal D; Yetimalar H
    Asian Pac J Cancer Prev; 2016; 17(2):497-501. PubMed ID: 26925634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center.
    Araujo KG; Jales RM; Pereira PN; Yoshida A; de Angelo Andrade L; Sarian LO; Derchain S
    Ultrasound Obstet Gynecol; 2017 Jun; 49(6):778-783. PubMed ID: 27194129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer.
    Zacharakis D; Thomakos N; Biliatis I; Rodolakis A; Simou M; Daskalakis G; Bamias A; Antsaklis A
    Acta Obstet Gynecol Scand; 2013 Mar; 92(3):285-92. PubMed ID: 23193945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
    Obeidat B; Latimer J; Crawford R
    Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
    Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
    Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of ovarian cancer by determination of CA 125 in different patohistologycal types of tumor according to age.
    Vranes HS; Klarić P; Kuna K; Kraljević Z; Gall V; Jukić M
    Coll Antropol; 2012 Jun; 36(2):425-9. PubMed ID: 22856226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
    Ma SK; Zhang HT; Sun YC; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the risk of malignancy of adnexal masses: validation of the ADNEX model in the hands of nonexpert ultrasonographers in a gynaecological oncology centre in China.
    He P; Wang JJ; Duan W; Song C; Yang Y; Wu QQ
    J Ovarian Res; 2021 Dec; 14(1):169. PubMed ID: 34857005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical picture of women with early stage ovarian cancer.
    Eltabbakh GH; Yadav PR; Morgan A
    Gynecol Oncol; 1999 Dec; 75(3):476-9. PubMed ID: 10600311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.